Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 3
2005 3
2006 4
2007 4
2008 3
2009 13
2010 23
2011 25
2012 42
2013 47
2014 50
2015 45
2016 36
2017 53
2018 50
2019 65
2020 82
2021 64
2022 68
2023 76
2024 88
2025 89
2026 65

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

867 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean bpdc (279 results)?
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): 2025 Update on Diagnosis, Pathophysiology, Risk Assessment, and Management.
Shimony S, Luskin MR, Gangat N, LeBoeuf NR, Feraco AM, Lane AA. Shimony S, et al. Am J Hematol. 2025 Aug;100(8):1408-1422. doi: 10.1002/ajh.27737. Epub 2025 Jun 17. Am J Hematol. 2025. PMID: 40525728 Free article. Review.
OVERVIEW: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic neoplasm that involves multiple organs, including the skin, bone marrow and blood, lymph nodes, and central nervous system. ...Eligibl …
OVERVIEW: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic …
Conventional Therapeutics in BPDCN Patients-Do They Still Have a Place in the Era of Targeted Therapies?
Poussard M, Angelot-Delettre F, Deconinck E. Poussard M, et al. Cancers (Basel). 2022 Aug 2;14(15):3767. doi: 10.3390/cancers14153767. Cancers (Basel). 2022. PMID: 35954431 Free PMC article. Review.
No benchmark treatment exists for blastic plasmacytoid dendritic cell neoplasm (BPDCN). Since the malignancy is chemo-sensitive, chemotherapy followed by hematopoietic stem cell transplantation remains an effective treatment. ...In …
No benchmark treatment exists for blastic plasmacytoid dendritic cell neoplasm (BPDCN). Since the …
Blastic Plasmacytoid Dendritic Cell Neoplasm.
Jain A, Sweet K. Jain A, et al. J Natl Compr Canc Netw. 2023 May;21(5):515-521. doi: 10.6004/jnccn.2023.7026. J Natl Compr Canc Netw. 2023. PMID: 37156483 Review.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with an aggressive clinical course and poor prognosis. ...Expression of CD4, CD56, and CD123 is the hallmark of BPDCN. The presence of 4 of CD4, …
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with an aggr …
Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics.
Adimora IJ, Wilson NR, Pemmaraju N. Adimora IJ, et al. Cancer. 2022 Aug 15;128(16):3019-3026. doi: 10.1002/cncr.34345. Epub 2022 Jun 21. Cancer. 2022. PMID: 35726525 Free article. Review.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy arising from precursor dendritic cells. BPDCN cells characteristically express several markers on their cell surfaces including CD1 …
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy arising from …
Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
Economides MP, Rizzieri D, Pemmaraju N. Economides MP, et al. Curr Hematol Malig Rep. 2019 Dec;14(6):515-522. doi: 10.1007/s11899-019-00556-2. Curr Hematol Malig Rep. 2019. PMID: 31853773 Review.
PURPOSE OF REVIEW: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, clinically aggressive hematologic malignancy that has heterogeneous presentation and can involve the skin, lymph nodes, and bone marrow. Recent advancement …
PURPOSE OF REVIEW: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, clinically aggr …
Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Alfayez M, Konopleva M, Pemmaraju N. Alfayez M, et al. Expert Opin Biol Ther. 2020 Feb;20(2):115-123. doi: 10.1080/14712598.2020.1701651. Epub 2019 Dec 17. Expert Opin Biol Ther. 2020. PMID: 31801379 Review.
Introduction: Advances and drug development in rare diseases, such as blastic plasmacytoid dendritic cell neoplasm (BPDCN), has historically been limited by small numbers of patients in the target population. In recent years, the developm …
Introduction: Advances and drug development in rare diseases, such as blastic plasmacytoid dendritic cell neo …
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.
Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M. Pemmaraju N, et al. N Engl J Med. 2019 Apr 25;380(17):1628-1637. doi: 10.1056/NEJMoa1815105. N Engl J Med. 2019. PMID: 31018069 Clinical Trial.
BACKGROUND: Blastic plasmacytoid dendritic-cell neoplasm (BPDCN) is an aggressive hematologic cancer that is caused by transformed plasmacytoid dendritic cells that overexpress interleukin-3 receptor subunit alpha (IL3RA or …
BACKGROUND: Blastic plasmacytoid dendritic-cell neoplasm (BPDCN) is an aggressive hematologic canc …
Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy.
Wilson NR, Konopleva M, Khoury JD, Pemmaraju N. Wilson NR, et al. Clin Lymphoma Myeloma Leuk. 2021 Nov;21(11):734-740. doi: 10.1016/j.clml.2021.05.018. Epub 2021 Jun 10. Clin Lymphoma Myeloma Leuk. 2021. PMID: 34226167 Review.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy arising from the aberrant transformation of plasmacytoid dendritic cells (pDCs) and involving skin, bone marrow, lymph nodes, and central …
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy arising from …
Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.
Pemmaraju N, Madanat YF, Rizzieri D, Fazal S, Rampal R, Mannis G, Wang ES, Foran J, Lane AA. Pemmaraju N, et al. Leuk Lymphoma. 2024 May;65(5):548-559. doi: 10.1080/10428194.2024.2305288. Epub 2024 Feb 23. Leuk Lymphoma. 2024. PMID: 38391126 Free article. Review.
BPDCN is an aggressive myeloid malignancy with a poor prognosis. It derives from the precursors of plasmacytoid dendritic cells and is characterized by CD123 overexpression, which is seen in all patients with BPDCN. The CD123-directed therapy tagraxofu …
BPDCN is an aggressive myeloid malignancy with a poor prognosis. It derives from the precursors of plasmacytoid dendritic …
Social Media and Internet Resources for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
Pemmaraju N, Gupta V, Thompson MA, Lane AA. Pemmaraju N, et al. Curr Hematol Malig Rep. 2016 Dec;11(6):462-467. doi: 10.1007/s11899-016-0340-3. Curr Hematol Malig Rep. 2016. PMID: 27492117 Review.
Utilization of online information sharing is rising, especially among those involved in rare blood cancer fields, which have generally featured a paucity of reliable, updated information. In particular, blastic plasmacytoid dendritic cell neoplasm …
Utilization of online information sharing is rising, especially among those involved in rare blood cancer fields, which have generally featu …
867 results